Firefly Neuroscience (NASDAQ:AIFF) has announced the discovery of a novel biomarker capable of estimating the biological age of a patient’s brain through its FDA-cleared Brain Network Analytics (BNA) technology platform.
According to Firefly, assessing brain age using EEG and BNA could revolutionize early Alzheimer’s screening, providing a proactive and scalable approach to patient care.
Gil Issachar, CTO of Firefly, stated, “To my knowledge, this marks the first instance where cognitive data measured by ERP has been successfully utilized by any technology platform for assessing biological brain age.”
“This innovative approach has the potential to illuminate various facets of human brain aging,” Mr. Issachar continued. “BNA data assessment, for example, is capable of finding a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia. By being able to measure brain age with EEG, we are potentially paving the way for a proactive and scalable approach to early screening and monitoring for Alzheimer’s patients.”
Greg Lipschitz, executive chairman of Firefly, noted, “This breakthrough underscores our commitment to pushing the boundaries of innovation in brain health, ultimately with the aim of making a meaningful impact on patients’ lives. I’m incredibly proud of our team for their dedication and ingenuity in bringing this vision to fruition.”
